Skip to main content
Top
Published in: Current Infectious Disease Reports 1/2014

01-01-2014 | Genitourinary Infections (J Sobel, Section Editor)

Urinary Tract Infection in Diabetes: Epidemiologic Considerations

Authors: Victoire de Lastours, Betsy Foxman

Published in: Current Infectious Disease Reports | Issue 1/2014

Login to get access

Abstract

The epidemiology of urnary tract infections (UTIs) among men and women with diabetes is similar to the epidemiology of those without: Women have greater risk than men, and frequency of sexual activity is a risk factor. The bacteriology and antibiotic susceptibility patterns also do not, in general, differ from those without diabetes. Although persons with diabetes are more likely to have asymptomatic bacteriuria, asymptomatic bacteriuria does not lead to increased risk of symptomatic infection, except during pregnancy or prior to genital-urinary or gastrointestinal surgery, and should not be treated otherwise. However, diabetes doubles the risk of UTI. The source of this increase is not well understood, although bladder dysfunction, which increases with duration of diabetes, and glycosuria are hypothesized mechanisms. As treatment using sodium glucose cotransporter 2 inhibitors—which lead to glycosuria—increases, there is a potential for the frequency of UTI to increase among those with diabetes.
Literature
1.
go back to reference Funfstuck R, Nicolle LE, Hanefeld M, Naber KG. Urinary tract infection in patients with diabetes mellitus. Clin Nephrol. 2012;77:40–8.PubMedCrossRef Funfstuck R, Nicolle LE, Hanefeld M, Naber KG. Urinary tract infection in patients with diabetes mellitus. Clin Nephrol. 2012;77:40–8.PubMedCrossRef
3.
go back to reference Baron EJ, Miller JM, Weinstein MP, et al. Executive summary: a guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a). Clin Infect Dis. 2013;57:485–8.PubMedCrossRef Baron EJ, Miller JM, Weinstein MP, et al. Executive summary: a guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a). Clin Infect Dis. 2013;57:485–8.PubMedCrossRef
4.
go back to reference Renko M, Tapanainen P, Tossavainen P, Pokka T, Uhari M. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care. 2011;34:230–5.PubMedCrossRef Renko M, Tapanainen P, Tossavainen P, Pokka T, Uhari M. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care. 2011;34:230–5.PubMedCrossRef
5.
go back to reference Nicolle LE, Zhanel GG, Harding GK. Microbiological outcomes in women with diabetes and untreated asymptomatic bacteriuria. World J Urol. 2006;24:61–5.PubMedCrossRef Nicolle LE, Zhanel GG, Harding GK. Microbiological outcomes in women with diabetes and untreated asymptomatic bacteriuria. World J Urol. 2006;24:61–5.PubMedCrossRef
6.
go back to reference Colgan R, Nicolle LE, McGlone A, Hooton TM. Asymptomatic bacteriuria in adults. Am Fam Physician. 2006;74:985–90.PubMed Colgan R, Nicolle LE, McGlone A, Hooton TM. Asymptomatic bacteriuria in adults. Am Fam Physician. 2006;74:985–90.PubMed
7.
go back to reference Harding GK, Zhanel GG, Nicolle LE, Cheang M. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med. 2002;347:1576–83.PubMedCrossRef Harding GK, Zhanel GG, Nicolle LE, Cheang M. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med. 2002;347:1576–83.PubMedCrossRef
8.
go back to reference Meiland R, Geerlings SE, Stolk RP, Netten PM, Schneeberger PM, Hoepelman AI. Asymptomatic bacteriuria in women with diabetes mellitus: effect on renal function after 6 years of follow-up. Arch Intern Med. 2006;166:2222–7.PubMedCrossRef Meiland R, Geerlings SE, Stolk RP, Netten PM, Schneeberger PM, Hoepelman AI. Asymptomatic bacteriuria in women with diabetes mellitus: effect on renal function after 6 years of follow-up. Arch Intern Med. 2006;166:2222–7.PubMedCrossRef
9.
go back to reference Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40:643–54.PubMedCrossRef Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40:643–54.PubMedCrossRef
10.
go back to reference Dalal S, Nicolle L, Marrs CF, Zhang L, Harding G, Foxman B. Long-term Escherichia coli asymptomatic bacteriuria among women with diabetes mellitus. Clin Infect Dis. 2009;49:491–7.PubMedCentralPubMedCrossRef Dalal S, Nicolle L, Marrs CF, Zhang L, Harding G, Foxman B. Long-term Escherichia coli asymptomatic bacteriuria among women with diabetes mellitus. Clin Infect Dis. 2009;49:491–7.PubMedCentralPubMedCrossRef
11.•
go back to reference Sanden AK, Johansen MB, Pedersen L, Lervang HH, Schonheyder HC, Thomsen RW. Change from oral antidiabetic therapy to insulin and risk of urinary tract infections in Type 2 diabetic patients: a population-based prescription study. J Diabetes Complicat. 2010;24:375–81. This large population-based study demonstrates that glycemic control is not associated with UTI risk. Sanden AK, Johansen MB, Pedersen L, Lervang HH, Schonheyder HC, Thomsen RW. Change from oral antidiabetic therapy to insulin and risk of urinary tract infections in Type 2 diabetic patients: a population-based prescription study. J Diabetes Complicat. 2010;24:375–81. This large population-based study demonstrates that glycemic control is not associated with UTI risk.
12.•
go back to reference Lin TL, Chen GD, Chen YC, Huang CN, Ng SC. Aging and recurrent urinary tract infections are associated with bladder dysfunction in type 2 diabetes. Taiwan J Obstet Gynecol. 2012;51:381–6. This prospective study presents results of urodynamic studies among 181 women with type 2 diabetes and lower bladder dysfunction. Lin TL, Chen GD, Chen YC, Huang CN, Ng SC. Aging and recurrent urinary tract infections are associated with bladder dysfunction in type 2 diabetes. Taiwan J Obstet Gynecol. 2012;51:381–6. This prospective study presents results of urodynamic studies among 181 women with type 2 diabetes and lower bladder dysfunction.
13.
go back to reference Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41:281–8.PubMedCrossRef Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41:281–8.PubMedCrossRef
14.
go back to reference Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia. 2007;50:549–54.PubMedCrossRef Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia. 2007;50:549–54.PubMedCrossRef
15.
go back to reference Scholes D, Hooton TM, Roberts PL, Gupta K, Stapleton AE, Stamm WE. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med. 2005;142:20–7.PubMedCentralPubMedCrossRef Scholes D, Hooton TM, Roberts PL, Gupta K, Stapleton AE, Stamm WE. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med. 2005;142:20–7.PubMedCentralPubMedCrossRef
16.
go back to reference Boyko EJ, Fihn SD, Scholes D, Abraham L, Monsey B. Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Am J Epidemiol. 2005;161:557–64.PubMedCrossRef Boyko EJ, Fihn SD, Scholes D, Abraham L, Monsey B. Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Am J Epidemiol. 2005;161:557–64.PubMedCrossRef
17.••
go back to reference Hirji I, Guo Z, Andersson SW, Hammar N, Gomez-Caminero A. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J Diabetes Complications. 2012;26:513–6. This study estimates the incidence of UTI among person with and without type 2 diabetes by age and gender using 17 years of data from the UK General Practice Research Database. Hirji I, Guo Z, Andersson SW, Hammar N, Gomez-Caminero A. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J Diabetes Complications. 2012;26:513–6. This study estimates the incidence of UTI among person with and without type 2 diabetes by age and gender using 17 years of data from the UK General Practice Research Database.
18.
go back to reference Hammar N, Farahmand B, Gran M, Joelson S, Andersson SW. Incidence of urinary tract infection in patients with type 2 diabetes. Experience from adverse event reporting in clinical trials. Pharmacoepidemiol Drug Saf. 2010;19:1287–92.PubMedCrossRef Hammar N, Farahmand B, Gran M, Joelson S, Andersson SW. Incidence of urinary tract infection in patients with type 2 diabetes. Experience from adverse event reporting in clinical trials. Pharmacoepidemiol Drug Saf. 2010;19:1287–92.PubMedCrossRef
19.
go back to reference Truzzi JC, Almeida FM, Nunes EC, Sadi MV. Residual urinary volume and urinary tract infection–when are they linked? J Urol. 2008;180:182–5.PubMedCrossRef Truzzi JC, Almeida FM, Nunes EC, Sadi MV. Residual urinary volume and urinary tract infection–when are they linked? J Urol. 2008;180:182–5.PubMedCrossRef
20.
go back to reference Drekonja DM, Rector TS, Cutting A, Johnson JR. Urinary tract infection in male veterans: treatment patterns and outcomes. JAMA Intern Med. 2013;173:62–8.PubMedCrossRef Drekonja DM, Rector TS, Cutting A, Johnson JR. Urinary tract infection in male veterans: treatment patterns and outcomes. JAMA Intern Med. 2013;173:62–8.PubMedCrossRef
21.
go back to reference Czaja CA, Rutledge BN, Cleary PA, Chan K, Stapleton AE, Stamm WE. Urinary tract infections in women with type 1 diabetes mellitus: survey of female participants in the epidemiology of diabetes interventions and complications study cohort. J Urol. 2009;181:1129–34. discussion 1134–5.PubMedCentralPubMedCrossRef Czaja CA, Rutledge BN, Cleary PA, Chan K, Stapleton AE, Stamm WE. Urinary tract infections in women with type 1 diabetes mellitus: survey of female participants in the epidemiology of diabetes interventions and complications study cohort. J Urol. 2009;181:1129–34. discussion 1134–5.PubMedCentralPubMedCrossRef
22.
go back to reference Wang MC, Tseng CC, Wu AB, et al. Bacterial characteristics and glycemic control in diabetic patients with Escherichia coli urinary tract infection. J Microbiol Immunol Infect. 2013;46:24–9.PubMedCrossRef Wang MC, Tseng CC, Wu AB, et al. Bacterial characteristics and glycemic control in diabetic patients with Escherichia coli urinary tract infection. J Microbiol Immunol Infect. 2013;46:24–9.PubMedCrossRef
23.
go back to reference Gorter KJ, Hak E, Zuithoff NP, Hoepelman AI, Rutten GE. Risk of recurrent acute lower urinary tract infections and prescription pattern of antibiotics in women with and without diabetes in primary care. Fam Pract. 2010;27:379–85.PubMedCrossRef Gorter KJ, Hak E, Zuithoff NP, Hoepelman AI, Rutten GE. Risk of recurrent acute lower urinary tract infections and prescription pattern of antibiotics in women with and without diabetes in primary care. Fam Pract. 2010;27:379–85.PubMedCrossRef
24.
go back to reference Schneeberger C, Stolk RP, Devries JH, Schneeberger PM, Herings RM, Geerlings SE. Differences in the pattern of antibiotic prescription profile and recurrence rate for possible urinary tract infections in women with and without diabetes. Diabetes Care. 2008;31:1380–5.PubMedCrossRef Schneeberger C, Stolk RP, Devries JH, Schneeberger PM, Herings RM, Geerlings SE. Differences in the pattern of antibiotic prescription profile and recurrence rate for possible urinary tract infections in women with and without diabetes. Diabetes Care. 2008;31:1380–5.PubMedCrossRef
25.
go back to reference Pertel PE, Haverstock D. Risk factors for a poor outcome after therapy for acute pyelonephritis. BJU Int. 2006;98:141–7.PubMedCrossRef Pertel PE, Haverstock D. Risk factors for a poor outcome after therapy for acute pyelonephritis. BJU Int. 2006;98:141–7.PubMedCrossRef
26.
go back to reference Kofteridis DP, Papadimitraki E, Mantadakis E, et al. Effect of diabetes mellitus on the clinical and microbiological features of hospitalized elderly patients with acute pyelonephritis. J Am Geriatr Soc. 2009;57:2125–8.PubMedCrossRef Kofteridis DP, Papadimitraki E, Mantadakis E, et al. Effect of diabetes mellitus on the clinical and microbiological features of hospitalized elderly patients with acute pyelonephritis. J Am Geriatr Soc. 2009;57:2125–8.PubMedCrossRef
27.
go back to reference Meiland R, Geerlings SE, De Neeling AJ, Hoepelman AI. Diabetes mellitus in itself is not a risk factor for antibiotic resistance in Escherichia coli isolated from patients with bacteriuria. Diabet Med. 2004;21:1032–4.PubMedCrossRef Meiland R, Geerlings SE, De Neeling AJ, Hoepelman AI. Diabetes mellitus in itself is not a risk factor for antibiotic resistance in Escherichia coli isolated from patients with bacteriuria. Diabet Med. 2004;21:1032–4.PubMedCrossRef
28.
go back to reference Bonadio M, Costarelli S, Morelli G, Tartaglia T. The influence of diabetes mellitus on the spectrum of uropathogens and the antimicrobial resistance in elderly adult patients with urinary tract infection. BMC Infect Dis. 2006;6:54.PubMedCentralPubMedCrossRef Bonadio M, Costarelli S, Morelli G, Tartaglia T. The influence of diabetes mellitus on the spectrum of uropathogens and the antimicrobial resistance in elderly adult patients with urinary tract infection. BMC Infect Dis. 2006;6:54.PubMedCentralPubMedCrossRef
29.
go back to reference Papazafiropoulou A, Daniil I, Sotiropoulos A, et al. Urinary tract infection, uropathogens and antimicrobial resistance in diabetic and nondiabetic patients. Diabetes Res Clin Pract. 2009;85:e12–3.PubMedCrossRef Papazafiropoulou A, Daniil I, Sotiropoulos A, et al. Urinary tract infection, uropathogens and antimicrobial resistance in diabetic and nondiabetic patients. Diabetes Res Clin Pract. 2009;85:e12–3.PubMedCrossRef
30.
go back to reference Doi Y, Park YS, Rivera JI, et al. Community-associated extended-spectrum beta-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis. 2013;56:641–8.PubMedCrossRef Doi Y, Park YS, Rivera JI, et al. Community-associated extended-spectrum beta-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis. 2013;56:641–8.PubMedCrossRef
31.
go back to reference Foxman B. Editorial commentary: extended-spectrum beta-lactamase-producing escherichia coli in the united states: time to rethink empirical treatment for suspected E. coli infections? Clin Infect Dis. 2013;56:649–51.PubMedCrossRef Foxman B. Editorial commentary: extended-spectrum beta-lactamase-producing escherichia coli in the united states: time to rethink empirical treatment for suspected E. coli infections? Clin Infect Dis. 2013;56:649–51.PubMedCrossRef
32.
go back to reference Soraas A, Sundsfjord A, Sandven I, Brunborg C, Jenum PA. Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae–a case–control study in a low prevalence country. PLoS One. 2013;8:e69581.PubMedCentralPubMedCrossRef Soraas A, Sundsfjord A, Sandven I, Brunborg C, Jenum PA. Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae–a case–control study in a low prevalence country. PLoS One. 2013;8:e69581.PubMedCentralPubMedCrossRef
33.
go back to reference Nicolas-Chanoine MH, Jarlier V, Robert J, et al. Patient's origin and lifestyle associated with CTX-M-producing Escherichia coli: a case–control-control study. PLoS One. 2012;7:e30498.PubMedCentralPubMedCrossRef Nicolas-Chanoine MH, Jarlier V, Robert J, et al. Patient's origin and lifestyle associated with CTX-M-producing Escherichia coli: a case–control-control study. PLoS One. 2012;7:e30498.PubMedCentralPubMedCrossRef
34.
go back to reference Boyle LD, Wilding JP. Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes. Expert Opin Emerg Drugs. 2013;18:375–91.PubMedCrossRef Boyle LD, Wilding JP. Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes. Expert Opin Emerg Drugs. 2013;18:375–91.PubMedCrossRef
35.
go back to reference Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–50.PubMedCrossRef Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–50.PubMedCrossRef
36.
go back to reference Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463–73.PubMedCentralPubMedCrossRef Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463–73.PubMedCentralPubMedCrossRef
37.
go back to reference Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–82.PubMedCentralPubMedCrossRef Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–82.PubMedCentralPubMedCrossRef
38.
go back to reference Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31–40.PubMedCrossRef Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31–40.PubMedCrossRef
39.
go back to reference Foxman B, Buxton M. Alternative approaches to conventional treatment of acute uncomplicated urinary tract infection in women. Curr Infect Dis Rep. 2013;15:124–9.PubMedCrossRef Foxman B, Buxton M. Alternative approaches to conventional treatment of acute uncomplicated urinary tract infection in women. Curr Infect Dis Rep. 2013;15:124–9.PubMedCrossRef
40.••
go back to reference Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:473–8. This meta analysis of safety data from 12 clinical trials, assessed the increased risk of UTI with treatment with dapagliflozin. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:473–8. This meta analysis of safety data from 12 clinical trials, assessed the increased risk of UTI with treatment with dapagliflozin.
Metadata
Title
Urinary Tract Infection in Diabetes: Epidemiologic Considerations
Authors
Victoire de Lastours
Betsy Foxman
Publication date
01-01-2014
Publisher
Springer US
Published in
Current Infectious Disease Reports / Issue 1/2014
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-013-0389-2
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine